Advertisement


Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease

2016 NCCN Annual Conference (1)

Advertisement

Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.



Related Videos

Lung Cancer

Douglas E. Wood, MD, on Lung Cancer Screening: Status and Patient Selection

Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.

Gynecologic Cancers

Wui-Jin Koh, MD, on Vulvar Cancer: Guidelines Update

Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center, discusses the multiple services required to best treat this rare cancer.

Health-Care Policy
Palliative Care

Joseph Simone, MD: Highlights of the 21st Annual NCCN Conference

Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.

Colorectal Cancer

Christopher Willett, MD, on Localized Rectal Cancer: Emerging Treatment Paradigms

Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.

Breast Cancer

Kevin C. Oeffinger, MD, on Controversies in Breast Cancer Screening Strategies

Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.

Advertisement

Advertisement




Advertisement